These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38742779)

  • 21. [When should bisphosphonate treatment be discontinued?].
    Eriksen EF; Halse J
    Tidsskr Nor Laegeforen; 2012 Aug; 132(14):1630-2. PubMed ID: 22875131
    [No Abstract]   [Full Text] [Related]  

  • 22. Randomized clinical trial comparing efficacy and safety of brand versus generic alendronate (Bonmax®) for osteoporosis treatment.
    Unnanuntana A; Jarusriwanna A; Songcharoen P
    PLoS One; 2017; 12(7):e0180325. PubMed ID: 28678853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
    Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
    Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users.
    Eiken PA; Prieto-Alhambra D; Eastell R; Abrahamsen B
    Osteoporos Int; 2017 Oct; 28(10):2921-2928. PubMed ID: 28664276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alendronate for the treatment of osteoporosis in men.
    Olszynski WP; Davison KS
    Expert Opin Pharmacother; 2008 Feb; 9(3):491-8. PubMed ID: 18220499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multicenter randomized double-masked comparative study of different preparations of alendronate in osteoporosis - monthly (four weeks) intravenous versus once weekly oral administrations.
    Shiraki M; Nakamura T; Fukunaga M; Sone T; Usami A; Inoue T
    Curr Med Res Opin; 2012 Aug; 28(8):1357-67. PubMed ID: 22769235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Osteoporotic fracture in menopausal women: alendronate reduces the risk].
    Bize R; Lamy O; Peytremann-Bridevaux I
    Rev Med Suisse; 2008 Dec; 4(183):2703. PubMed ID: 19157286
    [No Abstract]   [Full Text] [Related]  

  • 28. Use of generic alendronate in the treatment of osteoporosis.
    National Osteoporosis Foundation of South Africa
    S Afr Med J; 2006 Aug; 96(8):696-7. PubMed ID: 17019490
    [No Abstract]   [Full Text] [Related]  

  • 29. [Alendronate for treatment of osteoporoses].
    Harada A
    Nihon Rinsho; 2009 May; 67(5):943-7. PubMed ID: 19432114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab.
    Cummings SR; McCulloch C
    Osteoporos Int; 2020 Jun; 31(6):1019-1021. PubMed ID: 32246168
    [No Abstract]   [Full Text] [Related]  

  • 31. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
    AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis.
    Vis M; Bultink IE; Dijkmans BA; Lems WF
    Osteoporos Int; 2005 Nov; 16(11):1432-5. PubMed ID: 15883662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anabolic therapies for osteoporosis.
    Uihlein AV; Leder BZ
    Endocrinol Metab Clin North Am; 2012 Sep; 41(3):507-25. PubMed ID: 22877427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of alendronate on bone mineral density and bone turnover markers in post-gastrectomy osteoporotic patients.
    Iwamoto J; Uzawa M; Sato Y; Takeda T; Matsumoto H
    J Bone Miner Metab; 2010 Mar; 28(2):202-8. PubMed ID: 19690798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
    Landfeldt E; Lang A; Robbins S; Ström O
    Calcif Tissue Int; 2011 Sep; 89(3):234-45. PubMed ID: 21695544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pharmacological and clinical profile of once weekly alendronate for the treatment of osteoporosis (Fosamac 35 mg/Bonalon 35 mg)].
    Uchida S; Azuma Y; Taniguchi T; Arizono H; Shimizu T; Okaniwa M; Nakamura K; Ohta T
    Nihon Yakurigaku Zasshi; 2007 Oct; 130(4):305-12. PubMed ID: 17938517
    [No Abstract]   [Full Text] [Related]  

  • 37. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
    Langdahl BL; Marin F; Shane E; Dobnig H; Zanchetta JR; Maricic M; Krohn K; See K; Warner MR
    Osteoporos Int; 2009 Dec; 20(12):2095-104. PubMed ID: 19350340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparative study of the effects of daily minodronate and weekly alendronate on upper gastrointestinal symptoms, bone resorption, and back pain in postmenopausal osteoporosis patients.
    Yoshioka T; Okimoto N; Okamoto K; Sakai A
    J Bone Miner Metab; 2013 Mar; 31(2):153-60. PubMed ID: 23076293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study.
    Lee WY; Sun LM; Lin MC; Liang JA; Chang SN; Sung FC; Muo CH; Kao CH
    PLoS One; 2012; 7(12):e53032. PubMed ID: 23300854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study.
    Tee SI; Yosipovitch G; Chan YC; Chua SH; Koh ET; Chan YH; Tan SS; Tsou IY; Tan SH
    Arch Dermatol; 2012 Mar; 148(3):307-14. PubMed ID: 22105813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.